Cargando…

Antiplatelet Therapy Combined with Anastrozole Induces Features of Partial EMT in Breast Cancer Cells and Fails to Mitigate Breast-Cancer Induced Hypercoagulation

Thromboembolic complications are a leading cause of morbidity and mortality in cancer patients. Cancer patients often present with an increased risk for thrombosis including hypercoagulation, so the application of antiplatelet strategies to oncology warrants further investigation. This study investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xulu, Kutlwano R., Augustine, Tanya N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074114/ https://www.ncbi.nlm.nih.gov/pubmed/33923802 http://dx.doi.org/10.3390/ijms22084153

Ejemplares similares

Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches
por: Xulu, Kutlwano Rekgopetswe, et al.
Publicado: (2023)

Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
por: Xulu, Kutlwano R., et al.
Publicado: (2022)

HAART induces cell death in a cervical cancer cell line, HCS-2: A Scanning Electron Microscopy study
por: Xulu, Kutlwano Rekgopetswe, et al.
Publicado: (2017)

Tamoxifen induces hypercoagulation and alterations in ERα and ERβ dependent on breast cancer sub-phenotype ex vivo
por: Pather, K., et al.
Publicado: (2020)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

Escitalopram co-prescription in anastrozole-treated breast cancer patients
por: Ozyurt, Hazan, et al.
Publicado: (2022)

Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report
por: Wei, Min, et al.
Publicado: (2020)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Localized Cutaneous Adverse Event Induced by Anastrozole as Adjuvant Treatment for Breast Cancer: A Case Report
por: Tanaka, Aya, et al.
Publicado: (2019)

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
por: GHIMENTI, CHIARA, et al.
Publicado: (2013)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors
por: Eisner, Alvin, et al.
Publicado: (2007)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer
por: Glaser, Rebecca L., et al.
Publicado: (2014)

A Hypercoagulable Hematological Metastasis Breast Cancer Model
por: Yang, Wen-Jing, et al.
Publicado: (2021)

A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer
por: Lin, Ying, et al.
Publicado: (2014)

Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
por: Tugce Yesil, Devecioglu, et al.
Publicado: (2018)

Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells
por: Hassan, Firas, et al.
Publicado: (2017)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
por: Markopoulos, Christos, et al.
Publicado: (2010)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

EFFECT OF ANTICOAGULATION AND ANTIPLATELET AGENTS ON HYPERCOAGULABILITY STATES IN PATIENTS WITH COVID-19
por: UR, JEANNIE, et al.
Publicado: (2021)

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer
por: Anderson, T J, et al.
Publicado: (2002)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
por: Gangadhara, Sharath, et al.
Publicado: (2009)

Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
por: Aphinives, Potchavit, et al.
Publicado: (2014)

Joint symptoms associated with anastrozole and letrozole in patients with breast cancer: a retrospective comparative study
por: Morimoto, Yoshihito, et al.
Publicado: (2017)

Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer
por: Miller, W R, et al.
Publicado: (2002)

Tualang honey adjunct with anastrozole improve parenchyma enhancement of breast tissue in breast cancer patients: A randomized controlled trial
por: Hizan, Nik Shah, et al.
Publicado: (2018)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014)

Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines
por: Alyafee, Yusra A, et al.
Publicado: (2017)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
por: Sestak, I, et al.
Publicado: (2018)

Surface-Modification of Carbonate Apatite Nanoparticles Enhances Delivery and Cytotoxicity of Gemcitabine and Anastrozole in Breast Cancer Cells
por: Mozar, Fitya Syarifa, et al.
Publicado: (2017)

Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer
por: Kirwan, C. C., et al.
Publicado: (2019)

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
por: Kim, Yoo Jung, et al.
Publicado: (2020)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
por: Bojanić, Kristina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8bu43bi43lfti0bfpr6b0h6jag